NCT02975336 is a Phase 2 clinical trial of M2951 in Systemic Lupus Erythematosus, sponsored by EMD Serono Research & Development Institute, Inc..

Who is sponsoring NCT02975336?

NCT02975336 is sponsored by EMD Serono Research & Development Institute, Inc..

What drugs are being tested in NCT02975336?

Interventions in NCT02975336: Placebo, M2951, M2951, M2951, M2951.

What condition does NCT02975336 study?

NCT02975336 studies Systemic Lupus Erythematosus.

Is NCT02975336 still recruiting?

NCT02975336 is currently terminated. Last updated 12 April 2021.

Are results published for NCT02975336?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-04-12 · How we verify

NCT02975336

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II Study of M2951 in SLE

Terminated Phase 2 Results posted Last updated 12 April 2021

What this trial tests

Phase 2 trial testing Placebo in Systemic Lupus Erythematosus in 469 participants. Terminated before completion.

Timeline

4 January 2017

Primary endpoint
27 November 2019

23 March 2020

Quick facts

Lead sponsor	EMD Serono Research & Development Institute, Inc.
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	469
Start date	4 January 2017
Primary completion	27 November 2019
Estimated completion	23 March 2020
Sites	157 locations across Italy, Colombia, Japan, Malaysia, Mauritius, Taiwan, Poland, South Korea

Drugs / interventions tested

Placebo
M2951 — full drug profile →
M2951 — full drug profile →
M2951 — full drug profile →
M2951 — full drug profile →

Conditions studied

Systemic Lupus Erythematosus — all drugs for Systemic Lupus Erythematosus →

Sponsor

EMD Serono Research & Development Institute, Inc. — full company profile →

Who can join

Adults 18 to 75, any sex, with Systemic Lupus Erythematosus. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

DBPC Period: Number of Participants With Response Based on Systemic Lupus Erythematosus Responder Index 4 (SRI-4) at Week 52 Primary · Week 52

SRI-4 response was defined as greater than or equal to (\>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score, no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score, no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and no treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: a

Group	Value	95% CI
DBPC Period: Placebo	52
DBPC Period: M2951 25 mg QD	64
DBPC Period: M2951 75 mg QD	60
DBPC Period: M2951 50 mg BID	55

DBPC Period: Number of Participants With Response Based on Systemic Lupus Erythematosus Responder Index 6 (SRI-6) at Week 52 Primary · Week 52

SRI-6 response was defined as \>= 6-point reduction in SLEDAI-2K total score, no new BILAG A and no more than 1 new BILAG B domain score and no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ sys

Group	Value	95% CI
DBPC Period: Placebo	22
DBPC Period: M2951 25 mg QD	27
DBPC Period: M2951 75 mg QD	30
DBPC Period: M2951 50 mg BID	24

DBPC Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs According to National Cancer Institute-Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v4.03) Primary · Baseline up to Week 56

Adverse event (AE) was defined as any untoward medical occurrence in a participant, which does not necessarily have causal relationship with treatment. A serious AE was defined as an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged in participant hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs: events between first dose of study drug that were absent before treatment/that worsened relative to pre-treatment state up to 56 weeks. TEAEs included bot

Any TEAEs

Group	Value	95% CI
DBPC Period: Placebo	96
DBPC Period: M2951 25 mg QD	103
DBPC Period: M2951 75 mg QD	100
DBPC Period: M2951 50 mg BID	99

Any serious TEAE

Group	Value	95% CI
DBPC Period: Placebo	10
DBPC Period: M2951 25 mg QD	13
DBPC Period: M2951 75 mg QD	11
DBPC Period: M2951 50 mg BID	9

DBPC Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity According to National Cancer Institute-Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v4.03) Primary · Baseline up to Week 56

Severity of TEAEs were graded using NCI-CTCAE v4.03 toxicity grades, as follows: Grade 1= Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life-threatening and Grade 5 = Death. Number of participants with TEAEs by severity were reported.

Grade 1

Group	Value	95% CI
DBPC Period: Placebo	76
DBPC Period: M2951 25 mg QD	80
DBPC Period: M2951 75 mg QD	79
DBPC Period: M2951 50 mg BID	76

Grade 2

Group	Value	95% CI
DBPC Period: Placebo	63
DBPC Period: M2951 25 mg QD	77
DBPC Period: M2951 75 mg QD	72
DBPC Period: M2951 50 mg BID	78

Grade 3

Group	Value	95% CI
DBPC Period: Placebo	24
DBPC Period: M2951 25 mg QD	29
DBPC Period: M2951 75 mg QD	24
DBPC Period: M2951 50 mg BID	21

Grade 4

Group	Value	95% CI
DBPC Period: Placebo	1
DBPC Period: M2951 25 mg QD	1
DBPC Period: M2951 75 mg QD	0
DBPC Period: M2951 50 mg BID	2

Grade 5

Group	Value	95% CI
DBPC Period: Placebo	0
DBPC Period: M2951 25 mg QD	1
DBPC Period: M2951 75 mg QD	1
DBPC Period: M2951 50 mg BID	0

DBPC Period: Number of Participants With Clinically Significant Change From Baseline in Vital Signs Primary · Baseline up to Week 56

Vital signs included body temperature, systolic and diastolic blood pressure, pulse rate, respiratory rate, weight and height. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in vital signs were reported.

Group	Value	95% CI
DBPC Period: Placebo	0
DBPC Period: M2951 25 mg QD	0
DBPC Period: M2951 75 mg QD	0
DBPC Period: M2951 50 mg BID	0

DBPC Period: Number of Participants With Clinically Significant Changes From Baseline in 12-Lead Electrocardiogram (ECG) Findings Primary · Baseline up to Week 56

12-lead ECG recordings included rhythm, heart rate (as measured by RR interval), PR interval, QRS duration, and QT interval. The corrected QT interval (QTcF) was calculated using Fridericia's formula. 12-lead ECG recordings were obtained after the participants have rested for at least 10 minutes in semisupine position. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in 12-lead ECG findings were reported.

Group	Value	95% CI
DBPC Period: Placebo	0
DBPC Period: M2951 25 mg QD	0
DBPC Period: M2951 75 mg QD	0
DBPC Period: M2951 50 mg BID	0

DBPC Period: Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters Primary · Baseline up to Week 56

Laboratory investigation included hematology, biochemistry, urinalysis and coagulation. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in laboratory parameters were reported.

Group	Value	95% CI
DBPC Period: Placebo	0
DBPC Period: M2951 25 mg QD	0
DBPC Period: M2951 75 mg QD	0
DBPC Period: M2951 50 mg BID	0

DBPC Period: Mean Absolute Value of Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 2 Primary · Week 2

Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 2.

IgG

Group	Value	95% CI
DBPC Period: Placebo	14.56	± 5.367
DBPC Period: M2951 25 mg QD	13.75	± 4.652
DBPC Period: M2951 75 mg QD	14.37	± 5.536
DBPC Period: M2951 50 mg BID	12.81	± 3.847

IgA

Group	Value	95% CI
DBPC Period: Placebo	2.62	± 1.207
DBPC Period: M2951 25 mg QD	2.75	± 1.374
DBPC Period: M2951 75 mg QD	2.78	± 1.328
DBPC Period: M2951 50 mg BID	2.66	± 1.137

IgM

Group	Value	95% CI
DBPC Period: Placebo	1.12	± 0.662
DBPC Period: M2951 25 mg QD	1.22	± 0.890
DBPC Period: M2951 75 mg QD	1.09	± 0.697
DBPC Period: M2951 50 mg BID	1.18	± 0.776

DBPC Period: Mean Absolute Value of Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 4 Primary · Week 4

Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 4.

IgG

Group	Value	95% CI
DBPC Period: Placebo	14.92	± 5.497
DBPC Period: M2951 25 mg QD	13.60	± 4.590
DBPC Period: M2951 75 mg QD	14.21	± 4.828
DBPC Period: M2951 50 mg BID	12.73	± 3.771

IgA

Group	Value	95% CI
DBPC Period: Placebo	2.71	± 1.284
DBPC Period: M2951 25 mg QD	2.73	± 1.349
DBPC Period: M2951 75 mg QD	2.82	± 1.293
DBPC Period: M2951 50 mg BID	2.64	± 1.109

IgM

Group	Value	95% CI
DBPC Period: Placebo	1.12	± 0.699
DBPC Period: M2951 25 mg QD	1.18	± 0.824
DBPC Period: M2951 75 mg QD	1.06	± 0.676
DBPC Period: M2951 50 mg BID	1.16	± 0.745

DBPC Period: Mean Absolute Value of Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 12 Primary · Week 12

Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 12.

IgG:

Group	Value	95% CI
DBPC Period: Placebo	14.91	± 5.312
DBPC Period: M2951 25 mg QD	12.92	± 4.332
DBPC Period: M2951 75 mg QD	13.64	± 4.035
DBPC Period: M2951 50 mg BID	12.38	± 3.520

IgA

Group	Value	95% CI
DBPC Period: Placebo	2.72	± 1.321
DBPC Period: M2951 25 mg QD	2.73	± 1.340
DBPC Period: M2951 75 mg QD	2.88	± 1.363
DBPC Period: M2951 50 mg BID	2.68	± 1.021

IgM

Group	Value	95% CI
DBPC Period: Placebo	1.11	± 0.683
DBPC Period: M2951 25 mg QD	1.05	± 0.700
DBPC Period: M2951 75 mg QD	0.95	± 0.610
DBPC Period: M2951 50 mg BID	1.02	± 0.695

DBPC Period: Mean Absolute Value of Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 24 Primary · Week 24

Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 24.

IgG

Group	Value	95% CI
DBPC Period: Placebo	15.01	± 5.190
DBPC Period: M2951 25 mg QD	13.75	± 4.783
DBPC Period: M2951 75 mg QD	13.79	± 4.165
DBPC Period: M2951 50 mg BID	12.86	± 3.725

IgA

Group	Value	95% CI
DBPC Period: Placebo	2.79	± 1.430
DBPC Period: M2951 25 mg QD	2.89	± 1.460
DBPC Period: M2951 75 mg QD	2.98	± 1.391
DBPC Period: M2951 50 mg BID	2.78	± 1.091

IgM

Group	Value	95% CI
DBPC Period: Placebo	1.07	± 0.609
DBPC Period: M2951 25 mg QD	1.01	± 0.686
DBPC Period: M2951 75 mg QD	0.89	± 0.583
DBPC Period: M2951 50 mg BID	0.98	± 0.656

DBPC Period: Mean Absolute Value of Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 36 Primary · Week 36

Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 36.

IgG

Group	Value	95% CI
DBPC Period: Placebo	14.81	± 5.217
DBPC Period: M2951 25 mg QD	13.54	± 4.242
DBPC Period: M2951 75 mg QD	13.67	± 3.934
DBPC Period: M2951 50 mg BID	12.65	± 3.480

IgA

Group	Value	95% CI
DBPC Period: Placebo	2.72	± 1.378
DBPC Period: M2951 25 mg QD	2.89	± 1.418
DBPC Period: M2951 75 mg QD	3.01	± 1.420
DBPC Period: M2951 50 mg BID	2.86	± 1.073

IgM

Group	Value	95% CI
DBPC Period: Placebo	1.06	± 0.630
DBPC Period: M2951 25 mg QD	1.01	± 0.669
DBPC Period: M2951 75 mg QD	0.85	± 0.541
DBPC Period: M2951 50 mg BID	0.95	± 0.656

Adverse events — posted to ClinicalTrials.gov

Time frame: Double-Blind Placebo-Controlled: Baseline up to Week 56 Long-Term Extension: Up to Week 108. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

DBPC Period: Placebo

Serious: 10/117 (9%)

Deaths: 0/117

DBPC Period: M2951 25 mg QD

Serious: 13/118 (11%)

Deaths: 1/118

DBPC Period: M2951 75 mg QD

Serious: 11/117 (9%)

Deaths: 1/117

DBPC Period: M2951 50 mg BID

Serious: 9/117 (8%)

Deaths: 0/117

LTE: Placebo/ M2951 50 mg BID

Serious: 5/62 (8%)

Deaths: 0/62

LTE Period: M2951 25 mg QD/ M2951 50 mg BID

Serious: 5/69 (7%)

Deaths: 0/69

LTE Period: M2951 75 mg QD/ M2951 50 mg BID

Serious: 5/80 (6%)

Deaths: 0/80

LTE: M2951 50 mg BID/ M2951 50 mg BID

Serious: 7/72 (10%)

Deaths: 0/72

Serious adverse events (81 terms)

Reaction	System	DBPC Period: Placebo	DBPC Period: M2951 25 mg QD	DBPC Period: M2951 75 mg QD	DBPC Period: M2951 50 mg BID	LTE: Placebo/ M2951 50 mg …	LTE Period: M2951 25 mg QD…	LTE Period: M2951 75 mg QD…	LTE: M2951 50 mg BID/ M295…
Non-cardiac chest pain	General disorders	—	—	—	—	—	—	—	—
Otitis media	Infections and infestations	—	—	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—	—	—	—	—
Bone marrow failure	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—
Pancytopenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—
Pericarditis lupus	Cardiac disorders	—	—	—	—	—	—	—	—
Vertigo	Ear and labyrinth disorders	—	—	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Ascites	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Colitis	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Lupus enteritis	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Pancreatitis	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Dental cyst	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Chest pain	General disorders	—	—	—	—	—	—	—	—
Cholelithiasis	Hepatobiliary disorders	—	—	—	—	—	—	—	—
Hepatitis	Hepatobiliary disorders	—	—	—	—	—	—	—	—
Campylobacter sepsis	Infections and infestations	—	—	—	—	—	—	—	—
Cellulitis	Infections and infestations	—	—	—	—	—	—	—	—
Clostridium difficile infection	Infections and infestations	—	—	—	—	—	—	—	—
Diverticulitis	Infections and infestations	—	—	—	—	—	—	—	—
Gastroenteritis	Infections and infestations	—	—	—	—	—	—	—	—
Giardiasis	Infections and infestations	—	—	—	—	—	—	—	—
Pneumonia	Infections and infestations	—	—	—	—	—	—	—	—

Other adverse events (27 terms — click to expand)

Reaction	System	DBPC Period: Placebo	DBPC Period: M2951 25 mg QD	DBPC Period: M2951 75 mg QD	DBPC Period: M2951 50 mg BID	LTE: Placebo/ M2951 50 mg …	LTE Period: M2951 25 mg QD…	LTE Period: M2951 75 mg QD…	LTE: M2951 50 mg BID/ M295…
Urinary tract infection	Infections and infestations	—	—	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Nasopharyngitis	Infections and infestations	—	—	—	—	—	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—	—	—	—	—	—
Lymphopenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Influenza like illness	General disorders	—	—	—	—	—	—	—	—
Back Pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—
Abdominal pain upper	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Pharyngitis	Infections and infestations	—	—	—	—	—	—	—	—
Alanine aminotransferase increased	Investigations	—	—	—	—	—	—	—	—
Aspartate aminotransferase increased	Investigations	—	—	—	—	—	—	—	—
Amylase increased	Investigations	—	—	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Gamma-glutamyltransferase increased	Investigations	—	—	—	—	—	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—
Gastritis	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Gastroenteritis	Infections and infestations	—	—	—	—	—	—	—	—
Herpes zoster	Infections and infestations	—	—	—	—	—	—	—	—
Lipase increased	Investigations	—	—	—	—	—	—	—	—
Transaminases increased	Investigations	—	—	—	—	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—	—	—	—	—
Epistaxis	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—
Hypertension	Vascular disorders	—	—	—	—	—	—	—	—
Bronchitis	Infections and infestations	—	—	—	—	—	—	—	—

Most-reported serious reactions: Non-cardiac chest pain, Otitis media, Headache, Urinary tract infection, Bone marrow failure, Pancytopenia, Pericarditis lupus, Vertigo.

Data from ClinicalTrials.gov NCT02975336 adverse events section.

Sponsor's own description

M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study was to assess the Safety and Efficacy of M2951 in participants with Systemic Lupus Erythematosus (SLE).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.
Ringheim GE, Wampole M, Oberoi K. · · 2021 · cited 100× · PMID 34803999 · DOI 10.3389/fimmu.2021.662223
Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics.
Dai X, Fan Y, Zhao X. · · 2025 · cited 78× · PMID 40097390 · DOI 10.1038/s41392-025-02168-0
Bruton's Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives.
Robak E, Robak T. · · 2022 · cited 45× · PMID 35628931 · DOI 10.3390/jcm11102807
Bruton's Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease.
Neys SFH, Rip J, Hendriks RW, Corneth OBJ. · · 2021 · cited 41× · PMID 34609725 · DOI 10.1007/s40265-021-01592-0
Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Trial.
Wallace DJ, Dörner T, Pisetsky DS, Sanchez-Guerrero J, et al · · 2023 · cited 34× · PMID 36530019 · DOI 10.1002/acr2.11511
Bruton's Tyrosine Kinase Inhibition in Multiple Sclerosis.
Schneider R, Oh J. · · 2022 · cited 30× · PMID 36301434 · DOI 10.1007/s11910-022-01229-z
Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis.
Montalban X, Wallace D, Genovese MC, Tomic D, et al · · 2023 · cited 26× · PMID 36418156 · DOI 10.1136/jnnp-2022-328799
Interventions for cutaneous disease in systemic lupus erythematosus.
Hannon CW, McCourt C, Lima HC, Chen S, et al · · 2021 · cited 26× · PMID 33687069 · DOI 10.1002/14651858.cd007478.pub2

Verify or expand the search:

Other trials of M2951

Trials testing the same drug.

NCT04697511 — Drug-drug Interaction Study of Evobrutinib With Midazolam in Healthy Participants · Phase 1 · completed
NCT02784106 — Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis · Phase 2 · completed

Other recruiting trials for Systemic Lupus Erythematosus

Currently open trials in the same condition.

NCT06984341 — A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in P · Phase 1 · recruiting
NCT07526350 — MTS109 in Patients With Refractory Autoimmune Diseases · EARLY_PHASE1 · recruiting
NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting
NCT07371468 — A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD) · Phase 1 · recruiting

Other EMD Serono Research & Development Institute, Inc. trials

Trials by the same sponsor.

NCT07355218 — A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2) · Phase 3 · recruiting
NCT07332481 — A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease · Phase 3 · recruiting
NCT07360314 — Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07166601 — M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid · Phase 1 · recruiting
NCT07097259 — A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02975336 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by EMD Serono Research & Development Institute, Inc.
Last refreshed: 12 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02975336.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing